clofarabine has been researched along with sirolimus in 6 studies
| Studies (clofarabine) | Trials (clofarabine) | Recent Studies (post-2010) (clofarabine) | Studies (sirolimus) | Trials (sirolimus) | Recent Studies (post-2010) (sirolimus) |
|---|---|---|---|---|---|
| 424 | 101 | 280 | 20,711 | 2,368 | 11,516 |
| Protein | Taxonomy | clofarabine (IC50) | sirolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.25 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Mus musculus (house mouse) | 0.001 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0897 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.0042 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.225 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.225 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.9 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amadori, S; Ammatuna, E; Annino, L; Chiarini, F; Cilloni, D; Di Raimondo, F; Fazi, P; Fozza, C; La Sala, E; Lunghi, M; Martelli, AM; Martinelli, G; Meloni, G; Pagano, L; Pane, F; Ricci, F; Rossetti, E; Stasi, R; Venditti, A; Vignetti, M | 1 |
| Amadori, S; Bressanin, D; Cappellini, A; Chiarini, F; Falconi, M; Iacobucci, I; Lonetti, A; Martelli, AM; Martinelli, G; McCubrey, JA; Ognibene, A; Orsini, E; Pagliaro, P; Ricci, F; Tazzari, PL; Teti, G | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
1 review(s) available for clofarabine and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for clofarabine and sirolimus
| Article | Year |
|---|---|
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107).
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Salvage Therapy; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
4 other study(ies) available for clofarabine and sirolimus
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Bibliography. Current world literature. Therapeutic modalities.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Cancer Vaccines; Clofarabine; Cytokines; Epidermal Growth Factor; Glucocorticoids; Humans; Interleukin-2; Metalloporphyrins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sirolimus | 2004 |
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Topics: Adenine Nucleotides; ADP-ribosyl Cyclase 1; Allosteric Regulation; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Autophagy; Cell Line, Tumor; Clofarabine; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Initiation Factor-4F; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Humans; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Signal Transduction; Sirolimus; STAT3 Transcription Factor; Time Factors; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2012 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |